Care Setting¹

Perceived patient eligibility was higher among HCPs in the academic vs community settings for both BsAbs and CAR T-cell therapy

Reference

1. Zamagni E, Kevin B, Cormier N, et al. Differences across countries in healthcare provider confidence with CAR-T and bispecific antibody therapies for relapsed/refractory multiple myeloma. Presented at: EHA 2025 Congress; June 12-15, 2025; Milan, Italy. Poster PS1751.